Skip to main content

Table 10 Regression Analyses of Changes in Autism Severity vs. Urinary Metal Excretion (after 9th dose of DMSA in Phase 1) and Changes in Glutathione (Dglut).

From: Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part B - Behavioral results

  Adjusted R2 P-value Equation Most significant variables
Change in PDD-BI (n = 32) 0.59 0.002 7-rnd group (17.9 -2.62 Pb9 +0.230 Sn9 +102Tl9 -135Sb9 - 1.01 As9 -0.0695 Dglut)
1-rnd group (-32.7 -0.564 Pb9 +0.0755Sn9 +17.4 Tl9 +13.8 Sb9 -0.476 As9 +0.045 Dglut)
7-rnd group: Dglut***, As9**, Sb9**, Tl9**, Pb9*
     1-round group: No significant terms
Change in ATEC (n = 32) 0.25 0.02 7-rnd group (1.93 -7.82 Hg9 -0.352 As9)
1-rnd group (-4.91 -0.672 Hg9 -0.260 As9)
7-rnd group: Hg9**, As9*
     1-rnd group: No significant terms
Change in SAS (n = 29) 0.22 n.s. (not listed since not significant)  
Change in ADOS (comm.. + social) (n = 32) 0.18 n.s. (not listed since not significant)  
  1. Both treatment groups analyzed together, with individual coefficients for each group. Only the PDD-BI and ATEC yielded significant results, and only the 7-round group variables had significant coefficients. In the regression equation, the suffixes for the metals refer to the value at Baseline (B) and after the 9th dose of DMSA (9). Note that initial glutathione did not contribute to any of the final equations.